Poor Ron. He had to get off his bike after less than 2 miles on a gravel ride. The evolocumab is still exerting its effects. We’re thinking critically about the mechanisms of action of his musculoskeletal distress and responding accordingly. We are reducing inflammation, helping him to rebuild muscle, offering items to reduce the risk of […]